Want to see TMDX full AI Analyst Report?
TMDX Stock Chart & Stats
$92.22
$1.28(1.77%)
At close: 4:00 PM EDT
$92.22
$1.28(1.77%)
Day’s Range― - ―
52-Week Range$60.11 - $156.00
Previous CloseN/A
Volume216.03K
Average Volume (3M)855.75K
Market Cap
$3.06B
Enterprise Value$3.10K
Total Cash (Recent Filing)$472.68M
Total Debt (Recent Filing)$867.72M
Price to Earnings (P/E)19.5
Beta1.07
Next Earnings
Nov 04, 2026EPS Estimate
0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.42
Shares Outstanding34,675,144
10 Day Avg. Volume645,028
30 Day Avg. Volume855,751
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$93.11Price Target Upside0.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.5
Revenue Forecast (FY)$743.10M
Bulls Say, Bears Say
Bulls Say
Broad Revenue And Service GrowthRecord quarterly revenue and broad growth across product and service lines indicate expanding adoption of the OCS ecosystem. Continued liver, heart, and logistics gains support a durable volume-led revenue base, while the service mix adds case-based recurring activity as transplant utilization grows.
Raised Revenue OutlookManagement's raised 2026 revenue range implies continued 22%–25% growth even before PAD Aviation, ENHANCE Part B, or DENOVO contribute meaningfully. This embeds a substantial near-term growth outlook in the existing platform and reduces dependence on immediate new-program revenue.
Liquidity Supports ExpansionAn ending cash balance of about $473 million plus restricted cash, alongside positive operating cash flow, gives TransMedics capacity to fund OCS Kidney, Gen 3.0, logistics, and other expansion initiatives internally. That liquidity can support strategic investment while reducing immediate reliance on external financing.
Bears Say
Near-Term Margin CompressionThe reduced full-year adjusted operating-margin outlook signals that growth investments are consuming more near-term profitability. Higher R&D for OCS Kidney, Gen 3.0, ENHANCE, and DENOVO may build future capability, but the lower margin base can constrain earnings conversion over coming quarters.
Higher Leverage And Weaker Cash ConversionRising leverage alongside sharply lower free-cash-flow conversion reduces financial flexibility as the company funds expansion. If profitability softens further, greater fixed obligations and weaker internally generated cash could limit capacity to absorb execution setbacks or sustain investment.
Regulatory And Program Timing RiskPending IDE and approval milestones for ENHANCE Part B and DENOVO delay meaningful revenue contribution and make adoption timing less certain. This creates execution risk because planned heart, lung, and platform expansion depends on regulatory progress before commercial scale can develop.
TransMedics Group News
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $60.10 and its highest was $156.00 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $3.06B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Nov 04, 2026 which is in 55 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Aug 04, 2026. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.496 by -$0.056.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.3.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 34,675,144 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.44 in its last earnings report, missing expectations of $0.496. Following the earnings report the stock price went down -5.276%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$93.11 (0.97% Upside)
$93.11 (0.97% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 76%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 319.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
64.44%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TransMedics Group Inc
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and commercial picture: record revenue, strong product and service growth (notably liver and logistics), improved sequential gross margin, robust cash balance, and raised revenue guidance. At the same time, the company is investing heavily in strategic initiatives (OCS Kidney, Gen 3.0, ENHANCE, DENOVO, European logistics/PAD) which is elevating R&D and operating expenses, tempering near-term operating margin and introducing execution and timing risk (IDE approvals, PAD integration and international reimbursement). Overall, the fundamentals and long-term growth roadmap are strong, but near-term profitability will be impacted by deliberate, front-loaded investments and some timing uncertainties.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$93.11
▲(0.97% Upside)
Technical Analysis
Ownership Overview
3.55% Insiders
42.62% Mutual Funds
20.41% Other Institutional Investors
5.41% Public Companies and Individual Investors